You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

[177Lu]Lu-FF58

Showing 1 - 25 of 1,125
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme Trial (68Ga-FF58, 177Lu-FF58)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • (no location specified)
Jul 28, 2023

Prostate Cancer Trial in Beijing, Shanghai (Phase I:[177Lu]Lu-XT033 Injection, Phase II:[177Lu]Lu-XT033 Injection)

Not yet recruiting
  • Prostate Cancer
  • Phase I:[177Lu]Lu-XT033 Injection
  • Phase II:[177Lu]Lu-XT033 Injection
  • Beijing, Beijing, China
  • +1 more
Oct 7, 2023

Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma Trial (177Lu-DOTATOC)

Not yet recruiting
  • Neuroendocrine Tumors
  • +2 more
  • (no location specified)
Sep 13, 2023

Prostate Cancer Trial (AAA617)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Mar 27, 2023

Advanced Malignant Tumor Trial in Beijing ([ Lu-177]-Catalase)

Recruiting
  • Advanced Malignant Neoplasm
  • [ Lu-177]-Catalase
  • Beijing, Beijing, China
    Zhi Yang
Aug 2, 2023

Newly Diagnosed Glioblastoma Trial ([177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide)

Not yet recruiting
  • Newly Diagnosed Glioblastoma
  • (no location specified)
Feb 13, 2023

Breast Cancer Trial ([68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 22, 2023

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Metastatic Prostate Cancer Trial in Nanjing (177Lu-PSMA-0057)

Recruiting
  • Metastatic Prostate Cancer
  • Nanjing, Jiangsu, China
    Nanjing First Hospital
Sep 17, 2023

Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) Trial ([68Ga]Ga-DPI-4452,

Not yet recruiting
  • Clear Cell Renal Cell Cancer (ccRCC)
  • +2 more
  • (no location specified)
Jan 20, 2023

Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)

Not yet recruiting
  • Metastatic Neuroendocrine Tumor
  • Biospecimen Collection
  • +4 more
  • (no location specified)
Feb 10, 2023

Metastatic Malignant Tumor in the Viscera, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic

Not yet recruiting
  • Metastatic Malignant Neoplasm in the Viscera
  • +4 more
  • Lutetium Lu 177 Dotatate
  • (no location specified)
Jan 25, 2023

Prostate Cancer Trial in Wuxi (177Lu-labeled NY108)

Recruiting
  • Prostate Cancer
  • 177Lu-labeled NY108
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Apr 4, 2023

Extensive Stage Small Cell Lung Cancer Trial in France ([177Lu]Lu-DOTA-TATE, Tislelizumab, [68Ga]Ga-DOTA-TATE)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Lille, France
  • +6 more
Jan 23, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, Best supportive/best standard of care

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 2, 2023

Glioblastoma Trial in France, Portugal, Spain ([177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide)

Recruiting
  • Glioblastoma
  • Bron, France
  • +8 more
Jan 23, 2023

Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor Trial (procedure, drug, other)

Not yet recruiting
  • Metastatic Midgut Neuroendocrine Tumor
  • Unresectable Midgut Neuroendocrine Tumor
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Mar 16, 2023

Cancer Trial in Meldola, Cesena ([177Lu]Lu-PSMA I&T)

Not yet recruiting
  • Cancer
  • [177Lu]Lu-PSMA I&T
  • Meldola, Forlì, Italy
  • +1 more
May 10, 2023

Prostate Cancer Trial (Lutetium Lu 177 JH020002 Injection)

Not yet recruiting
  • Prostate Cancer
  • Lutetium Lu 177 JH020002 Injection
  • (no location specified)
Nov 14, 2023

Advanced Pancreatic Cancer and Cholangiocarcinoma Trial in Hangzhou (PRRT with 177Lu-EB-FAPI)

Recruiting
  • Advanced Pancreatic Cancer and Cholangiocarcinoma
  • PRRT with 177Lu-EB-FAPI
  • Hangzhou, Zhejiang, China
    First Affiliated Hospital of Zhejiang University
Oct 10, 2023

Prostate Cancer Trial ([177Lu]Lu-PSMA I&T, Stereotactic Radiotherapy)

Not yet recruiting
  • Prostate Cancer
  • [177Lu]Lu-PSMA I&T
  • Stereotactic Radiotherapy
  • (no location specified)
May 30, 2023

Solid Tumor, Unspecified, Adult Trial in Singapore (177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004

Not yet recruiting
  • Solid Tumor, Unspecified, Adult
  • 177Lu-LNC1004 Injection group 1 radionuclide therapy
  • +3 more
  • Singapore, Singapore
    National University Cancer Institute, Singapore National Univers
Feb 1, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.1 GBq (30 mCi) of 177Lu-P17-087
  • 1.1 GBq (30 mCi) of 177Lu-P17-088
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 30, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 23, 2023

Castration-Resistant Prostatic Cancer Trial ([Lu-177]-PNT2002)

Available
  • Castration-Resistant Prostatic Cancer
  • (no location specified)
Sep 11, 2023